Biostage Stock Fundamentals
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
Biostage fundamentals help investors to digest information that contributes to Biostage's financial success or failures. It also enables traders to predict the movement of Biostage OTC Stock. The fundamental analysis module provides a way to measure Biostage's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostage otc stock.
Biostage |
Biostage OTC Stock Shares Outstanding Analysis
Biostage's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Biostage Shares Outstanding | 11.64 M |
Most of Biostage's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostage is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Biostage has 11.64 M of shares currently outstending. This is 93.55% lower than that of the Biotechnology sector and 89.1% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 97.96% higher than that of the company.
Biostage Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biostage's current stock value. Our valuation model uses many indicators to compare Biostage value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biostage competition to find correlations between indicators driving Biostage's intrinsic value. More Info.Biostage is rated second in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biostage's earnings, one of the primary drivers of an investment's value.Biostage Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostage's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostage could also be used in its relative valuation, which is a method of valuing Biostage by comparing valuation metrics of similar companies.Biostage is currently under evaluation in shares outstanding category among its peers.
Biostage Fundamentals
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 | |||
| Current Valuation | 78.64 M | |||
| Shares Outstanding | 11.64 M | |||
| Shares Owned By Insiders | 50.95 % | |||
| Number Of Shares Shorted | 121.66 K | |||
| Price To Earning | (0.16) X | |||
| Price To Book | 28.47 X | |||
| EBITDA | (8.36 M) | |||
| Net Income | (7.98 M) | |||
| Cash And Equivalents | 4.64 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 115 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 2.26 X | |||
| Book Value Per Share | (0.16) X | |||
| Cash Flow From Operations | (2.63 M) | |||
| Short Ratio | 3.35 X | |||
| Earnings Per Share | (0.89) X | |||
| Target Price | 3.0 | |||
| Beta | -0.91 | |||
| Market Capitalization | 73.82 M | |||
| Total Asset | 1.87 M | |||
| Retained Earnings | (65.78 M) | |||
| Working Capital | 7.23 M | |||
| Current Asset | 7.88 M | |||
| Current Liabilities | 654 K | |||
| Net Asset | 1.87 M |
About Biostage Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostage's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostage using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostage based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts. Biostage operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |